Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer

Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a therapeutic milestone in the management of epithelial ovarian cancer. The concept of ‘synthetic lethality’ is exploited by PARPi in tumors with defects in DNA repair pathways, particularly homologous recombination deficiency. The use of PA...

Descripción completa

Detalles Bibliográficos
Autores principales: Veneziani, Ana C., Scott, Clare, Wakefield, Matthew J., Tinker, Anna V., Lheureux, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983116/
https://www.ncbi.nlm.nih.gov/pubmed/36872947
http://dx.doi.org/10.1177/17588359231157644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983116/
https://www.ncbi.nlm.nih.gov/pubmed/36872947
http://dx.doi.org/10.1177/17588359231157644

Ejemplares similares